Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib
Page 1 Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of …

BACKGROUND: Gefitinib was compared with pemetrexed as second‐line therapy in a
clinically selected population previously treated with platinum‐based chemotherapy …

8025 Background: ISTANA [IRESSA as Second-line Therapy in Advanced NSCLC-Korea]
study compared gefitinib (250 mg/day orally) with docetaxel (75 mg/m2 iv every 3 weeks) in …

Gefitinib, an orally active, selective inhibitor of epidermal growth factor-receptor tyrosine
kinase, is an effective treatment for patients with advanced non-small-cell lung cancer …

Should adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC) be the
standard of care? That question has been much debated since the presentation of results …

Methods The study patients met the following criteria: histologically confirmed, previously
treated advanced (stage IIIB or IV) or recurrent NSCLC; a measurable lesion;≥ 18 years of …

Background We conducted an analysis of gefitinib in patients with advanced non-small-cell
lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor …

Purpose: To examine potential markers of clinical benefit and the effects of erlotinib on the
epidermal growth factor receptor (EGFR) signaling pathway in advanced non–small cell …

Background: Both gefitinib and erlotinib are reversible epidermal growth factor receptor
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …

Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …